Shortage of functional groups on surface of poly(lactide-co-glycolide) (PLGA)-based drug delivery carriers always hampers its wide applications such as passive targeting and conjugation with targeting molecules. In this research, PLGA nanoparticles were modified with chitosan through physical adsorption and chemical binding methods. The surface charges were regulated by altering pH value in chitosan solutions. After the introduction of chitosan, zeta potential of the PLGA nanoparticle surface changed from negative charge to positive one, making the drug carriers more affinity to cancer cells. Functional groups were compared between PLGA nanoparticles and chitosan-modified PLGA nanoparticles. Amine groups were exhibited on PLGA nanoparticle ...
In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA na...
Chitosan-modified polylactic-co-glycolic acid (PLGA) nanoparticles with average diameter of 200 nm i...
Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failu...
Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) are well recognized as an ideal drug deliver...
Poly(lactic-co-glycolic acid) (PLGA) based nanoparticles have gained increasing attention in deliver...
Poly (D, L-Lactic-co-Glycolic Acid) (PLGA) nanoparticles were modified by adding cetyltrimethylammon...
A recently patented one-step methodology was used for the formulation of chitosan (CS) coated polyla...
The evolution of polymer based nanoparticles as a drug delivery carrier via pharmaceutical nano/micr...
The evolution of polymer based nanoparticles as a drug delivery carrier via pharmaceutical nano/micr...
Purpose: In order to improve siRNA delivery for possible clinical applications, we developed biodegr...
<div><p></p><p>Low molecular weight chitosan (LMWC) is a promising polymer for surface modification ...
Purpose To characterize and evaluate chitosan film containing PLGA nanoparticles (NPs) as a platform...
Despite the development of several progressive treatments, many effective anticancer drugs have fail...
The goal of this study was to develop an optimized drug delivery carrier for oral mucosa application...
Purpose: To evaluate poly (D,L-lactide-co-glycolide) PLGA nanoparticles modified by cetyltrimethyl a...
In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA na...
Chitosan-modified polylactic-co-glycolic acid (PLGA) nanoparticles with average diameter of 200 nm i...
Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failu...
Poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) are well recognized as an ideal drug deliver...
Poly(lactic-co-glycolic acid) (PLGA) based nanoparticles have gained increasing attention in deliver...
Poly (D, L-Lactic-co-Glycolic Acid) (PLGA) nanoparticles were modified by adding cetyltrimethylammon...
A recently patented one-step methodology was used for the formulation of chitosan (CS) coated polyla...
The evolution of polymer based nanoparticles as a drug delivery carrier via pharmaceutical nano/micr...
The evolution of polymer based nanoparticles as a drug delivery carrier via pharmaceutical nano/micr...
Purpose: In order to improve siRNA delivery for possible clinical applications, we developed biodegr...
<div><p></p><p>Low molecular weight chitosan (LMWC) is a promising polymer for surface modification ...
Purpose To characterize and evaluate chitosan film containing PLGA nanoparticles (NPs) as a platform...
Despite the development of several progressive treatments, many effective anticancer drugs have fail...
The goal of this study was to develop an optimized drug delivery carrier for oral mucosa application...
Purpose: To evaluate poly (D,L-lactide-co-glycolide) PLGA nanoparticles modified by cetyltrimethyl a...
In the current study, gefitinib loaded PLGA nanoparticles (GFT-PLGA-NPs) and chitosan coated PLGA na...
Chitosan-modified polylactic-co-glycolic acid (PLGA) nanoparticles with average diameter of 200 nm i...
Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failu...